Loading
A phase 1 trial of IMC-001 run by ImmuneOncia Therapeutics Inc., completed.
Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors is a phase 1 interventional study registered as NCT03644056 by ImmuneOncia Therapeutics Inc., with 15 participants enrolled, started 2018-03-22. Conditions recorded: Solid Tumor, Metastasis and Locally Advanced. Interventions recorded: IMC-001.
Shares IMC-001, ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/